Ζητάμε συγνώμη και σας ευχαριστούμε για την κατανόηση

Φίλες και Φίλοι,

Ζητάμε συγνώμη για την προβληματική εμφάνιση του ιστολογίου μας. (Έχουν αφαιρεθεί οι φωτογραφίες των αναρτήσεων).  Δυστυχώς φαίνεται πως έχουμε υποστεί επίθεση από άγνωστους hackers. Ελπίζουμε πως θα καταφέρουμε να αποκαταστήσουμε σύντομα τη σωστή λειτουργία του ιστολογίου μας.

Ευχαριστούμε για την κατανόηση σας

Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics

One of Pfizer's  top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis  are promising to launch their versions as soon as Pfizer's monopoly expires.

Pfizer will appeal, but barring success in a higher court, the company stands to lose billions in sales; Celebrex (celecoxib) brought in $2.9 billion in net sales last year, $1.9 billion in the U.S. Morningstar analyst Damien Conover says the ruling could cost Pfizer $1 billion this year and $2 billion next. And Mark Schoenebaum, an ISI Group analyst, figures Celebrex generics could lop 12 cents off Pfizer's 2014 earnings per share, if they make their debut in May.

Roche and Bayer expand their partnership into multiple projects

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced that it has entered into a multi-year agreement with Bayer Pharma AG (Bayer) to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer's portfolio of targeted therapy projects. This new agreement extends an already existing collaboration and focuses on the development of diagnostic tests for Bayer's biomarker targeted therapeutics from early discovery through commercialization.

Branded pharma revenues to rise 2%-3% in 2014, says Fitch

Revenues for brand-name drugmakers will rise just 2%-3% in 2014, forecasts ratings agency Fitch, but it adds that global pharmaceuticals is still one of its highest-rated industries, and that the sector outlook remains “stable.” 

 Moderate pressure from patent expiries, cost-containment policies in the European Union (EU) and weak employment in the US will be only partly offset by uptake of new products and strong growth in emerging markets, it says in a new report, which expects no significant divergence in the trend in profitability between US and EU-based drugmakers next year.

Fitch also believes that industry will find patent expiry levels in 2014 to be “manageable.” Patents on roughly $34 billion-worth of branded drug sales are set to expire during the year - accounting for approximately 3.6% of global market sales - compared to $28 billion this year and $55 billion in 2012.